Twenty-five year evolution of medical hormonal therapy for prostate cancer.
Publication
, Other
Moul, JW
Published in: BJU Int
January 2009
Duke Scholars
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
January 2009
Volume
103
Issue
2
Start / End Page
145 / 146
Location
England
Related Subject Headings
- Urology & Nephrology
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oligopeptides
- Male
- Leuprolide
- Humans
- Gonadotropin-Releasing Hormone
- Clinical Trials, Phase III as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Moul, J. W. (2009). Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. England. https://doi.org/10.1111/j.1464-410X.2008.08271.x
Moul, Judd W. “Twenty-five year evolution of medical hormonal therapy for prostate cancer.” BJU Int, January 2009. https://doi.org/10.1111/j.1464-410X.2008.08271.x.
Moul JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. Vol. 103, BJU Int. 2009. p. 145–6.
Moul, Judd W. “Twenty-five year evolution of medical hormonal therapy for prostate cancer.” BJU Int, vol. 103, no. 2, Jan. 2009, pp. 145–46. Pubmed, doi:10.1111/j.1464-410X.2008.08271.x.
Moul JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 2009. p. 145–146.
Published In
BJU Int
DOI
EISSN
1464-410X
Publication Date
January 2009
Volume
103
Issue
2
Start / End Page
145 / 146
Location
England
Related Subject Headings
- Urology & Nephrology
- Randomized Controlled Trials as Topic
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oligopeptides
- Male
- Leuprolide
- Humans
- Gonadotropin-Releasing Hormone
- Clinical Trials, Phase III as Topic